{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 3.0', 'CONFIDENTIAL', 'BCX7353-302', 'Table 5.', 'Clinical Laboratory Evaluations', 'Chemistry', 'Coagulation', 'Albumin', 'Prothrombin time (PT) and international', 'Alkaline phosphatase (ALP)', 'normalized ratio (INR)', 'Alanine aminotransferase (ALT)', 'Activated partial thromboplastin time (aPTT)', 'Aspartate aminotransferase (AST)', 'Bilirubin (total and direct)', 'Pregnancy Test', 'Blood glucose', 'Blood urea nitrogen (BUN)', 'Serum (screening) and urine (other scheduled', 'visits) BHCG for women of childbearing potential', 'Electrolytes (calcium, sodium, potassium,', 'chloride, bicarbonate [CO2], phosphorus)', 'only', 'Lipid panel (total cholesterol, triglycerides)', 'Drug screen', 'Creatine kinase', 'Amphetamines', 'Creatinine and calculated CLCR', 'Barbiturates', 'Gamma-glutamyl transferase (GGT)', 'Benzodiazepines', 'Lactate dehydrogenase (LDH)', 'Cocaine', 'Total serum protein', 'Opiates', 'Uric acid', 'Methamphetamine', 'If amylase is > 2 X ULN, reflex to lipase', 'Ecstasy', 'Urinalysis', 'Specific gravity', 'Blood', 'Additional Tests', 'Bilirubin', 'FSH for women postmenopausal VI <2 years', 'Glucose', 'Hepatitis B surface antigen, hepatitis C', 'Leukocytes', 'antibody, HIV antibody; if HCV antibody', 'Ketones', 'positive, reflex to HCV RNA testing', 'Nitrites', 'Troponin I', 'pH', 'Troponin T', 'Protein', 'Neutrophil gelatinase-associated lipocalin', 'Urobilinogen', '(NGAL)', 'Microalbumin to creatinine ratio', 'CK-MB', 'Reflex Microscopy if dipstick is abnormal', 'C3', 'Hematology', 'HLA typing', 'Hemoglobin', 'Sample for possible exploratory', 'Hematocrit', 'pharmacogenomic analysis (optional)', 'Erythrocytes', 'C1-INH level and function', 'Mean corpuscular haemoglobin (MCH)', 'C1-INH antigenic level', 'Mean corpuscular haemoglobin concentration', 'C4', '(MCHC)', 'If GGT, AST or ALT is > 3 X ULN, reflex to', 'Mean corpuscular volume (MCV)', 'carbohydrate deficient transferrin (CDT)', 'White blood cell count, with differential', 'If GGT, AST or ALT is > 3 X ULN, reflex to', '(lymphocytes, monocytes, neutrophils,', 'urinary ethyl glucuronide', 'eosinophils, and basophils)', 'Platelets', '74']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 3.0', 'CONFIDENTIAL', 'BCX7353-302', 'CLCR will be calculated using the Cockcroft-Gault formula and actual body weight (ABW):', 'CLcr (mL/min) = (140 - age in years) X ABW (kg) (x 0.85 for females)', '72 X serum creatinine (in mg/dL)', '11.2.7.', 'Screening for Human Immunodeficiency Virus, Hepatitis B, and Hepatitis C', 'Serology', 'Blood samples will be collected at screening for serologic testing for evidence of HIV, chronic', 'hepatitis B, and chronic hepatitis C infection.', '11.2.8.', 'HLA Typing', 'All subjects will have a blood sample drawn at Baseline (or any other time point on study if not', 'obtained at Baseline) for HLA typing. Samples will be sent to a central laboratory for analysis.', 'The results will not be communicated back to the Investigator or subjects because the results are', 'not intended for diagnostic or prognostic purposes and will be used in a research related fashion', 'only. Relationships between safety assessment findings and HLA typing results may be', 'examined on a meta-study basis', '11.2.9.', 'Pregnancy Testing', 'FSH will be measured at screening in women declaring themselves postmenopausal 2 years to', 'establish childbearing status. At screening, a serum pregnancy test should also be drawn in the', 'event a woman subject postmenopausal 2 years is found to be of childbearing potential.', 'For women and adolescents of childbearing potential, a serum pregnancy test will be', 'administered at screening. Urinary pregnancy tests will be assessed at all subsequent visits. A', 'serum pregnancy test should immediately be drawn and sent for analysis for any positive urine', 'pregnancy test.', 'Urine pregnancy tests will be provided by the central laboratory but will be resulted locally.', 'Women of childbearing potential who enroll at sites in Europe will be dispensed urinary', 'pregnancy tests as noted in the Schedule of Assessments to be completed at home at Weeks 16,', '22, 40, 44, 52, 56, 64, 68, 76, 80, 88, and 92 and then monthly between clinic visits. Sites will', 'confirm negative test results by telephone and record in source documents.', '11.2.10.', 'HAE Diagnostic Confirmation', 'C1-INH functional level and C4 are to be drawn at the screening visit; it is recommended that', 'samples not be drawn within 3 days of C1-INH administration (eg, use for treatment of an HAE', 'attack).', 'If a subject has a normal C4 level (as is the case in a small percentage of subjects with HAE)', 'drawn at the screening visit, the site may draw another C4 level during an attack. A normal C4', 'level drawn during an attack excludes the subject from study participation.', 'Alternatively, the site may also utilize SERPING-1 gene mutational analysis or a family history', 'of C1-INH deficiency in the case of a normal C4 level. To utilize a family history of C1-INH', 'deficiency to establish an HAE diagnosis for eligibility, the Investigator should document this as', \"a source file note based on either the Investigator's personal knowledge (ie, if a relative of the\", '75']\n\n###\n\n", "completion": "END"}